July 24, 2019 | English | عربي
Add to Twitter
Dabigatran’s safety and efficacy established for management of VTE in children
• First studies to assess treatment and prevention of recurrent venous thromboembolism (VTE) with dabigatran etexilate in children

• The Phase IIb/III DIVERSITY study demonstrated that the efficacy and safety profile of dabigatran was comparable to standard of care (SOC) for the treatment of children with acute VTE1

• A second Phase III study reinforced the safety profile in children with persistent VTE risk factors receiving dabigatran for prevention of recurrent VTE2